EUVIMEDOpdag EUVIMED
Open access · CC BY-NC-ND 4.0

Therapeutic drug monitoring of methotrexate in patients with Crohn's disease

Maartje M van de Meeberg iD, Herma H Fidder, Bas Oldenburg, Janani Sundaresan, Eduard A Struys, Nahid S M Montazeri, Wout G N Mares, Nofel Mahmmod, Dirk P van Asseldonk, Maurice W M D Lutgens, Johan P Kuyvenhoven, Svend T Rietdijk and 7 more

Alimentary Pharmacology & Therapeutics · 2023

DOI: 10.1111/apt.17719 ↗

At a glance

Journal article in Alimentary Pharmacology & Therapeutics, 2023. Written by Maartje M van de Meeberg and 18 co-authors. Institution: Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam University Me…. Major MEDLINE topics: Crohn Disease, Drug-Related Side Effects and Adverse Reactions, Chemical and Drug Induced Liver Injury, Antirheumatic Agents. Cited 16 times so far (Crossref); 44 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Maag Lever Darm Stichting.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Therapeutic drug monitoring (TDM) has the potential to improve efficacy and diminish side effects. Measuring methotrexate‐polyglutamate (MTX‐PG) in erythrocytes might enable TDM for methotrexate in patients with Crohn's disease (CD).

Aim

To investigate the relationship between MTX‐PGs and methotrexate drug survival, efficacy and toxicity Methods In a multicentre prospective cohort study, patients with CD starting subcutaneous methotrexate without biologics were included and followed for 12 months. Primary outcome was subcutaneous methotrexate discontinuation or requirement for step‐up therapy. Secondary outcomes included faecal calprotectin (FCP), Harvey Bradshaw Index (HBI), hepatotoxicity and gastrointestinal intolerance. Erythrocyte MTX‐PGs were analysed at weeks 8, 12, 24 and 52 or upon treatment discontinuation.

Results

We included 80 patients with CD (mean age 55 ± 13y, 35% male) with a median FCP of 268 μg/g (IQR 73–480). After the 12‐month visit, 21 patients (26%) were still on subcutaneous methotrexate monotherapy. Twenty‐one patients stopped because of disease activity, 29 because of toxicity, and four for both reasons. Five patients ended study participation or stopped methotrexate for another reason. A higher MTX‐PG 3 concentration was associated with a higher rate of methotrexate drug survival (HR 0.86, 95% CI 0.75–0.99), lower FCP ( β −3.7, SE 1.3, p < 0.01) and with biochemical response (FCP ≤250 if baseline >250 μg/g; OR 1.1, 95% CI 1.0–1.3). Higher MTX‐PGs were associated with less gastrointestinal intolerance. There was no robust association between MTX‐PGs and HBI or hepatotoxicity.

Conclusions

Higher MTX‐PG 3 concentrations are related to better methotrexate drug survival and decreased FCP levels. Therefore, MTX‐PG 3 could be used for TDM if a target concentration can be established.

Subjects

MeSH terms (MEDLINE)

Crohn DiseaseDrug-Related Side Effects and Adverse ReactionsChemical and Drug Induced Liver InjuryAntirheumatic AgentsHumansMaleAdultMiddle AgedAgedFemaleMethotrexateProspective StudiesDrug MonitoringTreatment Outcome

Substances

MethotrexateAntirheumatic Agents

Authors and institutions

  • Department of Gastroenterology and Hepatology, Amsterdam Gastroenterology Endocrinology Metabolism (AGEM) Research Institute, Amsterdam University Medical Centre, VU University Amsterdam, Amsterdam, the Netherlands.
  • Department of Gastroenterology and Hepatology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
  • Department of Clinical Chemistry, Amsterdam UMC, Amsterdam, the Netherlands.
  • Biostatistics Unit, Department of Gastroenterology and Hepatology, Amsterdam UMC, Amsterdam, the Netherlands.
  • Department of Gastroenterology and Hepatology, Gelderse Vallei Hospital, Ede, the Netherlands.
  • Department of Gastroenterology and Hepatology, St. Antonius Hospital, Nieuwegein, the Netherlands.

ORCID profiles: Maartje M van de Meeberg

Funding

  • Maag Lever Darm Stichting

Cite

APA

van de Meeberg, M. M., Fidder, H. H., Oldenburg, B., Sundaresan, J., Struys, E. A., Montazeri, N. S. M., Mares, W. G. N., Mahmmod, N., van Asseldonk, D. P., Lutgens, M. W. M. D., Kuyvenhoven, J. P., Rietdijk, S. T., Nissen, L. H. C., Koehestanie, P., de Boer, N. K. H., de Jonge, R., Bouma, G., Bulatović Ćalasan, M., & Dutch Initiative on Crohn and Colitis (ICC) (2023). Therapeutic drug monitoring of methotrexate in patients with Crohn's disease. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.17719

Vancouver

van de Meeberg MM, Fidder HH, Oldenburg B, Sundaresan J, Struys EA, Montazeri NSM, et al. Therapeutic drug monitoring of methotrexate in patients with Crohn's disease. Alimentary Pharmacology & Therapeutics. 2023. doi:10.1111/apt.17719

BibTeX
@article{vandeMeeberg2023,
  author = {van de Meeberg, Maartje M and Fidder, Herma H and Oldenburg, Bas and Sundaresan, Janani and Struys, Eduard A and Montazeri, Nahid S M and Mares, Wout G N and Mahmmod, Nofel and van Asseldonk, Dirk P and Lutgens, Maurice W M D and Kuyvenhoven, Johan P and Rietdijk, Svend T and Nissen, Loes H C and Koehestanie, Parweez and de Boer, Nanne K H and de Jonge, Robert and Bouma, Gerd and Bulatović Ćalasan, Maja and Dutch Initiative on Crohn and Colitis (ICC), Dutch Initiative on Crohn and Colitis (ICC)},
  title = {Therapeutic drug monitoring of methotrexate in patients with Crohn's disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  doi = {10.1111/apt.17719}
}
Start for free →